Next Phase Newsletter

An impact investment arm of a non-profit organization manages an evergreen fund and is interested in therapeutics, diagnostics or screening technology, medical devices, digital health or tech enabled services that align with the firm’s mission to advance the fight against cancer. The firm will invest in companies of all stages of development (excluding public companies), and looks for companies that are advancing science, reducing disparities, and promoting health care sustainability; though there is a preference for Seed and Series A stage companies. The firm’s typical check size ranges from $250K-$2 million per round and reserves additional funds for follow-on investments. The firm is currently looking to co-invest, and will consider global opportunities, but is currently investing mostly in the US.

While relatively agnostic to technology within therapeutics, medical devices, diagnostics and digital health, The firm will only invest in companies relevant to the indication of oncology.

The firm is looking to co-invest in private companies only.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based firm is investing from its second fund and manages about $150M AUM. The firm invests in pre-seed through Series A rounds in exchange for equity. Typical allocations average in the $500k to $1.5M range. The main areas of interest for the firm are data-driven healthcare/biotech, enterprise software, and deep tech. The firm tends to focus on companies headquartered in North America.

The firm invests in software and hardware with proprietary algorithmic and design principles. For example, big data, AI/ML, robotics, and autonomous vehicles are of interest. Within data-driven health/biotech, the firm focuses on core technology innovations in computational health, synthetic biology, and digital health. Their portfolio includes companies involved in deep learning for medical imaging, genomics platforms and tools, in silico therapeutics discovery, large scale custom DNA synthesis, and a digital health platform consisting of software and integrated wearable hardware.

The firm seeks to work with management teams that have prior entrepreneurial experience or domain-specific technical or medical experience in the market they are targeting. They typically have regular check-ins with portfolio companies and can take on board seats.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Venture Capital firm based in USA is currently investing out of their fourth fund. The firm looks to make early-stage investments, typically in Series A companies. Investments range from $1M to $1.5M in the initial round with up to $3M in reserve for follow on financings. The firm invests across the United States. The firm prefers to syndicate rounds with additional strong institutional investors, and is willing to serve as lead investor.

The firm invests solely in early-stage medical device and diagnostics companies. The firm generally looks for companies that have created an early working prototype or obtained a proof-of-concept with supporting data.

The firm seeks privately-held companies and maintains positive and productive working relationships with its portfolio companies, providing proactive assistance. The firm is more open to taking significant scientific and technical risk as opposed to sales and marketing challenges, preferring its investment to fund clinical trials and regulatory approval.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global venture capital and commercial development firm based in the USA has raised five life science-focused venture funds its flagship Venture Capital business unit and is currently investing out of its fifth fund. In addition, the firm recently closed on a new fund that is investing in companies domiciled in Singapore, Hong Kong and China. The firm generally looks to support companies with lead assets that can reach high value inflection points in 3-4 years and will consider opportunities in US, Canada, Europe, Singapore, Hong Kong and China.

The firm is currently seeking companies developing therapeutics or medical technologies to treat true unmet medical needs. The firm is therapeutic area agnostic, although the firm has historically been most active in immunology, oncology, and rare diseases. The firm typically prefers to invest in Series A/B rounds with a preference for lead assets between 18 months pre-IND and Phase 2a. Within devices, the firm generally prefers to invest in later stage opportunities, particularly those devices that have received market approval with early revenue.

The firm does not have any specific requirements for a firm’s management team. The firm is an active investor and seeks a director or observer position on a company’s board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A seed fund focuses on applied AI technologies, and invests in three verticals: Digital Health, Enterprise and Automation. Within Digital Health, the firm invests in companies developing AI/ML, software-based technologies in the sectors of digital health, diagnostics and R&D services. The firm will invest $250K-500K in seed-stage companies based in the US and Canada, and will consider all companies, as long as they have a good business model.

Within healthcare, the firm invests in companies that are primarily software-based. In addition to digital health companies, the firm will consider diagnostics and R&D services companies, such as smart lab monitoring, genomics-based diagnostics, or AI-driven drug discovery.

The firm will invest only in companies whose primary base of operations is in the US and Canada, and with those focused on the US/Canadian market. While the firm may take a board or observer seat after investing, they do not require it for all of their investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A multi-family venture fund based in the US is an active investor in the medical device sector, and is interested in opportunities in the western United States. Initial investments are typically about $150,000 with the potential for follow-on investments totaling $1 million and may be structured as equity or as debt. In the recent past, the firm has allocated new investments at a rate of approximately one every two months. The firm offers support and expertise to portfolio companies but does not seek a board seat.

The firm is interested in medical technology and lab equipment, including electro-mechanical medical devices, active implantable devices, and surgical instruments. The firm invests only in companies that have already developed a prototype of their product,  filed a patent application and have animal data.

The firm seeks to invest in strong management teams with prior experience in the medical device industry. The firm prefers to make investments with the potential to exit within 3-4 years.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An active early-stage life science development group founded by a private company currently backs more than 15 programs and companies, based on technologies and assets developed internally or in-licensed from academic medical institutions. The most advanced company in the portfolio has completed a Series D round, and total investment across all technologies exceeds $150 million. The firm has a dual development strategy. The firm partners with academic inventors to found, manage, and develop companies to a point of exit or strategic partnering. When founding companies, the firm leverages non-dilutive grant funding where available alongside their investment group. The firm can also support early clinical-stage companies looking for financial and management support to perform clinical proof of concept studies; specifically a combination of investor funding and management support to round out the capabilities of the existing team. The firm and its affiliated investor groups have the ability to lead investment rounds of up to $20 million while also providing any required management support through its experienced team, including in preclinical, clinical and business development.

The firm invests across the biosciences space including Therapeutics, Diagnostics, and Medical Devices although the primary focus is on Therapeutics. The group is opportunistic in terms of subsectors and indications. Historically, the group has been active with companies developing novel therapeutics including drugs for defending against inhaled pathogenic threats, treatment of asthma, cancer, autoimmune diseases, and hearing loss, a biomedical assay platform technology, molecular diagnostics, antioxidant nanoparticles, robotic and imaging technologies, and cardiovascular devices.

The firm is interested in connecting with companies looking to generate clinical proof-of-concept data and that require funding as well as management support to complement the existing team. We are especially interested in companies that may have an interest in relocating to Houston.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.